Literature DB >> 22490510

Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.

Archana Raamanathan1, Glennon W Simmons, Nicolaos Christodoulides, Pierre N Floriano, Wieslaw B Furmaga, Spencer W Redding, Karen H Lu, Robert C Bast, John T McDevitt.   

Abstract

Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a three-dimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2% and 1.9% and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R(2) = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490510      PMCID: PMC3677577          DOI: 10.1158/1940-6207.CAPR-11-0508

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  47 in total

1.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

Authors:  J R van Nagell; P D DePriest; M B Reedy; H H Gallion; F R Ueland; E J Pavlik; R J Kryscio
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

Review 2.  Lab-on-a-chip devices for global health: past studies and future opportunities.

Authors:  Curtis D Chin; Vincent Linder; Samuel K Sia
Journal:  Lab Chip       Date:  2006-10-27       Impact factor: 6.799

3.  The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?

Authors:  Beth Y Karlan; Martin McIntosh
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

Review 4.  Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.

Authors:  Monica R McLemore; Bradley Aouizerat
Journal:  Biol Res Nurs       Date:  2005-04       Impact factor: 2.522

5.  Bead-based ELISA for validation of ovarian cancer early detection markers.

Authors:  Nathalie Scholler; Meghan Crawford; Alicia Sato; Charles W Drescher; Kathy C O'Briant; Nancy Kiviat; Garnet L Anderson; Nicole Urban
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

7.  Validation of serum biomarkers for detection of early-stage ovarian cancer.

Authors:  Vladimir Nosov; Feng Su; Malaika Amneus; Michael Birrer; Terry Robins; Jenny Kotlerman; Srinivasa Reddy; Robin Farias-Eisner
Journal:  Am J Obstet Gynecol       Date:  2009-03-14       Impact factor: 8.661

8.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

Authors:  S J Skates; F J Xu; Y H Yu; K Sjövall; N Einhorn; Y Chang; R C Bast; R C Knapp
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

9.  Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.

Authors:  M K Tuxen; G Sölétormos; P Dombernowsky
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 10.  Proteomics as a tool for biomarker discovery.

Authors:  Elise C Kohn; Nilofer Azad; Christina Annunziata; Amit S Dhamoon; Gordon Whiteley
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

View more
  11 in total

1.  Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids.

Authors:  Nicolaos Christodoulides; Richard De La Garza; Glennon W Simmons; Michael P McRae; Jorge Wong; Thomas F Newton; Regina Smith; James J Mahoney; Justin Hohenstein; Sobeyda Gomez; Pierre N Floriano; Humberto Talavera; Daniel J Sloan; David E Moody; David M Andrenyak; Thomas R Kosten; Ahmed Haque; John T McDevitt
Journal:  Drug Alcohol Depend       Date:  2015-05-22       Impact factor: 4.492

Review 2.  Recent advancements in fabrication of nanomaterial based biosensors for diagnosis of ovarian cancer: a comprehensive review.

Authors:  Rinky Sha; Sushmee Badhulika
Journal:  Mikrochim Acta       Date:  2020-02-19       Impact factor: 5.833

3.  Next Generation Programmable Bio-Nano-Chip System for On-Site Detection in Oral Fluids.

Authors:  Nicolaos Christodoulides; Richard De La Garza; Glennon W Simmons; Michael P McRae; Jorge Wong; Thomas F Newton; Thomas R Kosten; Ahmed Haque; John T McDevitt
Journal:  J Drug Abuse       Date:  2015-11-23

Review 4.  Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

Authors:  Sarah A Engelberth; Nadine Hempel; Magnus Bergkvist
Journal:  Crit Rev Oncog       Date:  2014

5.  A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.

Authors:  Basil H Shadfan; Archana R Simmons; Glennon W Simmons; Andy Ho; Jorge Wong; Karen H Lu; Robert C Bast; John T McDevitt
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-11

Review 6.  Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Authors:  Juliane M Liberto; Sheng-Yin Chen; Ie-Ming Shih; Tza-Huei Wang; Tian-Li Wang; Thomas R Pisanic
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

7.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Authors:  Eleftherios P Diamandis; Robert C Bast; Phil Gold; T Ming Chu; John L Magnani
Journal:  Clin Chem       Date:  2012-11-30       Impact factor: 8.327

8.  Gold nanorods for ovarian cancer detection with photoacoustic imaging and resection guidance via Raman imaging in living mice.

Authors:  Jesse V Jokerst; Adam J Cole; Dominique Van de Sompel; Sanjiv S Gambhir
Journal:  ACS Nano       Date:  2012-11-02       Impact factor: 15.881

Review 9.  Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation.

Authors:  Nicolaos J Christodoulides; Michael P McRae; Timothy J Abram; Glennon W Simmons; John T McDevitt
Journal:  Front Public Health       Date:  2017-05-22

Review 10.  Different Approaches to Develop Nanosensors for Diagnosis of Diseases.

Authors:  Nina Arndt; Huong D N Tran; Run Zhang; Zhi Ping Xu; Hang T Ta
Journal:  Adv Sci (Weinh)       Date:  2020-10-28       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.